Vivek Subbiah: Honored to participate in the AACR -Industry Roundtable with Lilian Siu
Vivek Subbiah posted on LinkedIn:
“Such a delight and honor to participate in the AACR -Industry Roundtable with American Association for Cancer Research elect Dr. Lillian Siu
Today Oct 8th is a historic day that Nobel Prize for Physics was awarded for foundational models leading to todays AI
Today is also the day for the debate on AI.
Wow! Amazing coincidence or did the AACR team know in advance
Looking forward for the special session
TOPIC: The integration of early cancer detection and AI-driven technologies will become standard practice in oncology and increase cancer cure rates by 2034.
Moderated by the amazing Dr. Lecia Sequist
Enthusiast: YES!
– Vivek Subbiah
Realist: NO!
– Alexander T. Pearson.”
Vivek Subbiah is the Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute (USA). He is the former Executive Director of Oncology Research and former Associate Professor in the Department of Investigational Cancer Therapeutics at the MD Anderson Cancer. He focuses on translational cancer research and the design and implementation of early-phase biomarker-driven clinical trials. His work specifically targets antibody-drug conjugates, radiopharmaceuticals, immunoconjugates, and basket trials. He has also received the Yvonne Award 2024 by OncoDaily in the “Voice of Oncology” category.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023